MicroRNA as a therapeutic agent
The disclosure provides, inter alia, hybridized nucleic acid sequences and compounds comprising Toll-like receptor 9-binding nucleic acid sequences and nucleic acid sequences comprising a microRNA passenger strand sequence hybridized to a microRNA guide strand sequence; pharmaceutical compositions comprising the hybridized nucleic acid sequences and compounds; and the use of the hybridized nucleic acid sequences, compounds, and pharmaceutical compositions to treat medical conditions, such as cancer and inflammatory diseases.
1 . A compound of Formula (I): (1) or Formula (II):
R 1 -L1-R 2 (I) or
wherein:
R 1 is a CpG oligodeoxynucleotide (ODN);
L 1 and L 2 are independently a linking group;
R 2 and R 3 are independently a hybridized nucleic acid comprising a miR146a passenger strand hybridized to a miR146a guide strand; wherein the miR146a passenger strand has a sequence comprising SEQ ID NO:2, 3, 4, 5, 37, or 39, and the miR146a guide strand has a sequence comprising SEQ ID NO:7, 8, 36, or 38.
2 . The compound of claim 1 , wherein the miR146a passenger strand sequence comprises SEQ ID NO:2, 3, 4, or 5, and the miR146a guide strand sequence comprises SEQ ID NO:7 or 8.
3 . The compound of claim 1 , wherein the 3′ end of R 1 is covalently bonded to L 1 .
4 . The compound of claim 1 , wherein the microRNA passenger strand sequence is covalently bonded to the linking group; and wherein the microRNA guide strand sequence is hybridized to the microRNA passenger strand sequence.
5 . The compound of claim 1 , wherein the CpG ODN is a CpG-A ODN, a CpG-B ODN, a CpG-C ODN, or a combination of two or more thereof.
6 . The compound claim 1 , wherein the CpG ODN is CpG ODN 19, CpG ODN 1585, CpG ODN 2216, CpG ODN 2336, CpG ODN 1668, CpG ODN 1826, CpG ODN 2006, CpG ODN 2007, CpG ODN BW006, CpG ODN D-SL01, CpG ODN 2395, CpG ODN M362, CpG ODN D-SL03, or a combination of two or more thereof.
7 . The compound of claim 1 , wherein R 1 comprises the sequence of any one of SEQ ID NOS: 9-18, 33-35, and 40-44.
8 . The compound of claim 1 , wherein L 1 and L 2 are independently a bond, a nucleic acid sequence, a DNA sequence, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination of two or more thereof.
9 . The compound of claim 1 , wherein L 1 and L 2 are independently is a substituted 6 to 60 membered heteroalkylene.
10 . The compound of claim 1 , wherein L 1 and L 2 are independently:
wherein X 1 is independently —OH or —O − , and n is an integer from 1 to 10.
11 . The compound of claim 1 , wherein L 1 and L 2 are independently is —(CH 2 CH 2 O)—; a 5 or 6 membered substituted or unsubstituted heteroarylene comprising one or two nitrogen atoms; or a 5 or 6 membered substituted or unsubstituted heterocycloalkylene comprising an oxygen atom, a nitrogen atom, or a combination thereof.
12 . The compound of claim 1 , wherein the 5′ end of the microRNA passenger strand sequence is covalently bonded to L 1 .
13 . The compound of claim 1 , wherein in the compound of Formula (I):
(i) the 3′ end of R 1 is bonded to L 1 ;
(ii) R 2 is the hybridized nucleic acid sequence; wherein the 5′ end of the miR146a passenger strand sequence is covalently bonded to L 1 ; and wherein the miR146a passenger strand sequence comprises SEQ ID NO:2 and the miR146a guide strand sequence comprises SEQ ID NO:7 or SEQ ID NO:8; and
(iii) L 1 is
wherein X 1 is independently —OH or —O − , and n is an integer from 4 to 6.
14 . The compound of claim 13 , wherein R 1 comprises SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO:17, or SEQ ID NO: 18.
15 . The compound of claim 1 , wherein the miR146a passenger strand has a sequence comprising SEQ ID NO:2, and the miR146a guide strand has a sequence comprising SEQ ID NO:7 or SEQ ID NO:8.
16 . The compound of claim 1 , wherein the miR146a passenger strand has a sequence comprising SEQ ID NO:37, and the miR146a guide strand has a sequence comprising SEQ ID NO:36.
17 . The compound of claim 1 , wherein the miR146a passenger strand has a sequence comprising SEQ ID NO:39, and the miR146a guide strand has a sequence comprising SEQ ID NO:38.
18 . The compound of claim 1 , wherein in the compound of Formula (II):
(i) the 3′ end of R 1 is bonded to L 1 ;
(ii) R 2 is the hybridized nucleic acid sequence; wherein the 5′ end of the miR146a passenger strand sequence is covalently bonded to L 1 ; the miR146a passenger strand sequence comprises SEQ ID NO:2 and the miR146a guide strand sequence comprises SEQ ID NO:6 or SEQ ID NO:7;
(iii) R 3 is the hybridized nucleic acid sequence; wherein the 5′ end of the miR146a passenger strand sequence is covalently bonded to L 2 ; wherein the miR146a passenger strand sequence comprises SEQ ID NO:2 and the miR146a guide strand sequence comprises SEQ ID NO:7 or SEQ ID NO:8; and
(iv) L 1 and L 2 are independently:
(a) substituted or unsubstituted heteroalkylene;
(b) 5 or 6 membered substituted or unsubstituted heteroarylene comprising one or two nitrogen atoms;
(c) 5 or 6 membered substituted or unsubstituted heterocycloalkylene comprising an oxygen atom, a nitrogen atom, or a combination thereof; or
(d) a combination of two or more of the foregoing.
19 . A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.
20 . A method of treating cancer or an inflammatory disease in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound of claim 1 .
21 . A method of treating cytokine release syndrome, sepsis, acute myeloid leukemia, B-cell lymphoma, or myelodysplastic syndrome in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound of claim 1 .